Tests BBO-11818 in adults with advanced KRAS mutant cancers
Tests BBO-11818, a KRAS-targeting drug, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Key facts
- Where
- Melbourne, AustraliaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced lung, pancreatic, colorectal or other solid tumors that carry a KRAS G12 mutation and cannot be removed by surgery or have spread.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced tumor that cannot be removed by surgery, or metastatic tumor (NSCLC, PDAC, CRC or other solid tumor). Disease must be measurable by RECIST v1.1. ECOG performance status 0-1.
- Biomarker or test result
- Tumor with a KRAS G12A, G12C, G12D, G12S or G12V mutation
Main reasons for not taking part
- Another cancer within the last 2 years, as specified in the protocol
- Brain metastases that have not been treated
Read by machine on 12 November 2026.
Where in Australia
- Peter MacCallum Cancer CentreMelbourne, AustraliaContact: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Trial code
- NCT06917079
- Record updated
- 2 June 2026
- Original description
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.Read full original descriptionShow less
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Inclusion: Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation; Measurable disease by RECIST v1.1; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; Life expectancy >24 weeks; Adequate organ function.
Exclusion: Malignancy within the last 2 years as specified in the protocol; Untreated brain metastases; Other inclusion/exclusion criteria are specified in the protocol.